FDA clears Orthovita's Vitoss bone filler:
This article was originally published in Clinica
Orthovita has received US FDA 510(k) clearance for its synthetic cancellous bone void filler for repairing bone defects in the spine, extremities and pelvis. The Vitoss scaffold, is made of a resorbable calcium phosphate, which has a porous, fine-particle structure that allows the product to become saturated with marrow, blood and nutrients required for bone growth and remodelling. The product will be launched in February, making it the Malvern, Pennsylvania company's first product on the US orthopaedic market. It is already available for sale in Europe.
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.